--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced ...

Background: Psoriasis, an immune-mediated chronic inflammatory skin disease, is characterized by keratinocyte proliferation and inflammatory cell infiltration. T ripterygium wilfordii is a potential ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Cutting-edge bispecific and tri-specific antibody therapies headline Innovent’s research portfolio. SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" ...

For hematologic cancers, the past decade was marked by the rise of alternative immunotherapies such as antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric ...

1Tumor Immune Analysis Core, Office of Research & Development, Taipei Medical University, Taipei, Taiwan.

Led by Arthur Lahr, Avidicure is developing dual agonistic, multifunctional, and avidity-engineered antibodies, “AVC-Boosters”, that can safely deliver targeted and potent cancer monotherapy. The ...

The FDA has approved Akeso’s penpulimab-kcqx, a PD-1 monoclonal antibody, for two indications treating nasopharyngeal carcinoma (NPC). The drug is now indicated in combination with chemotherapy as a ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting several autoimmune diseases. The funding consists of a $30 million series ...